| Signaling effectors underlying pathologic growth and remodeling of the heart. | |
| | |
MedLine Citation:
|
PMID: 23281408 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cardiovascular disease is the number one cause of mortality in the Western world. The heart responds to many cardiopathological conditions with hypertrophic growth by enlarging individual myocytes to augment cardiac pump function and decrease ventricular wall tension. Initially, such cardiac hypertrophic growth is often compensatory, but as time progresses these changes become maladaptive. Cardiac hypertrophy is the strongest predictor for the development of heart failure, arrhythmia, and sudden death. Here we discuss therapeutic avenues emerging from molecular and genetic studies of cardiovascular disease in animal models. The majority of these are based on intracellular signaling pathways considered central to pathologic cardiac remodeling and hypertrophy, which then leads to heart failure. We focus our discussion on selected therapeutic targets that have more recently emerged and have a tangible translational potential given the available pharmacologic agents that could be readily evaluated in human clinical trials. |
| | |
Authors:
|
Jop H van Berlo; Marjorie Maillet; Jeffery D Molkentin |
Related Documents
:
|
23493668 - The cardiomyocyte as a source of cytokines in cardiac injury. 19840558 - The chemokine network in relation to infarct size and left ventricular remodeling follo... 10642758 - Ad hoc coronary intervention. 18340288 - Underutilization of evidence-based medications in acute st elevation myocardial infarct... 9152488 - Collagen synthesis is upregulated in mitral valves subjected to altered stress. 2331998 - Vagal heart rate control after percutaneous transluminal coronary angioplasty. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2013-01-02 |
Journal Detail:
|
Title: The Journal of clinical investigation Volume: 123 ISSN: 1558-8238 ISO Abbreviation: J. Clin. Invest. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-01-02 Completed Date: 2013-03-11 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 7802877 Medline TA: J Clin Invest Country: United States |
Other Details:
|
Languages: eng Pagination: 37-45 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pediatrics, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Howard Hughes Medical Institute, Cincinnati, Ohio 45229-3039, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Arrhythmias, Cardiac / drug therapy, etiology, metabolism, mortality, pathology, physiopathology Cardiomegaly / complications, drug therapy*, metabolism*, mortality, pathology, physiopathology Clinical Trials as Topic Death, Sudden / epidemiology Disease Models, Animal Heart Failure / drug therapy, etiology, metabolism, mortality, pathology, physiopathology Humans Signal Transduction* Ventricular Remodeling* |
| Grant Support | |
ID/Acronym/Agency:
|
//Howard Hughes Medical Institute |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Adaptive immunity in atherogenesis: new insights and therapeutic approaches.
Next Document: Calcium cycling proteins and heart failure: mechanisms and therapeutics.